Skip to content

Leveraging the Emergency Department to Engage African American Women in HIV Pre-Exposure Prophylaxis

Leveraging the Emergency Department to Engage African American Women in HIV Pre-Exposure Prophylaxis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03930654
Acronym
IWPrEP
Enrollment
40
Registered
2019-04-29
Start date
2019-11-13
Completion date
2021-12-31
Last updated
2022-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

African American women, HIV risk, substance use, sexual risk

Brief summary

African American (AA) women are more vulnerable to HIV infection than other women. Truvada, when used as pre-exposure prophylaxis (PrEP), is one of the most effective approaches for HIV prevention; however, PrEP use among AA women remains low and has not responded to traditional interventions. This study proposes for the first time an innovative computer-based motivational intervention, increasing PrEP uptake (iPrEP), which couples motivational messages woven into a traditional survey to raise awareness of risky sex and substance use behaviors.

Interventions

BEHAVIORALiPrEP

* iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV. * Women will receive the iPrEP intervention on an iPAD Air tablet device * iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument * iPrEP uses qualitative themes * iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence * Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument * Scales were modified (in some cases) for cultural competency and tailoring to women

BEHAVIORALUsual Care

* Women will receive usual care * Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use * Social worker will offer a list of substance abuse treatment referral agencies

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Masking description

Patients will be assigned to either an intervention or usual care

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Current HIV negative status (based on ED' HIV test outcome) * Condomless sex in the last 3 months * Substance use in the last 3 months * HIV testing during ED visit (usual care) * Has a non-emergent health condition * Has a working mobile device with them

Exclusion criteria

* Ineligible for PrEP (see eligibility criteria to the right) * Assigned male at birth * An HIV positive status * Currently taking medication that are known contraindications for PrEP (brand name: Truvada) * Currently on PrEP

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with an increased willingness for pre-exposure prophylaxis (PrEP) uptake1 monthParticipants will be assessed for social norms and risk.

Secondary

MeasureTime frameDescription
Number of participants with decrease in substance use1 month
Number of participants with a new sexually transmitted disease diagnosis1 month
Number of participants with HIV seroconversion1 month
iPrEP feasibility and acceptability as assessed by the number of participants who believe that they had more information to make a better decision about being in a PrEP program after completing the survey interventionbaselineAs part of the survey, participants will be asked if they believe that they had more information to make a better decision about being in a PrEP program after completing the survey intervention.
Number of participants with decreased high risk sex1 month
iPrEP feasibility and acceptability as assessed by how often participants relied on the survey questions being read aloud to be able to answer thembaselineAs part of the survey, participants will asked As you completed this questionnaire, how often did you rely on the questions being read aloud to be able to answer them? and will choose one of the following 4 categorical choices: For all the questions, For most of the questions, For some of the questions, For none of the questions
iPrEP feasibility and acceptability as assessed by number of participants who needed help from site staff in order to complete the surveybaselineAs part of the survey, participants will be asked if they needed help from site staff in order to complete the survey.
iPrEP feasibility and acceptability as assessed by the kind of help that participants needed from site staff in order to complete the surveybaselineAs part of the survey, participants will asked What kind of help did you need? Please check all that apply and will choose among the following categorical 4 choices: I had to have some of the questions explained to me, I needed help using the iPAD, I needed to have the questionnaire read to me by a staff member, I needed help for a different reason
iPrEP feasibility and acceptability as assessed by how participants felt about the length of the surveybaselineAs part of the survey, participants will asked how they felt about the length of the survey and will choose one of the following 3 categorical choices: Too long, Too short, The right length
iPrEP feasibility and acceptability as assessed by how much participant liked or disliked completing the surveybaselineAs part of the survey, participants will asked How much did you like or dislike completing this questionnaire? and will choose one of the following 5 categorical choices: Liked it, Liked it somewhat, Neither liked nor disliked it, Disliked it somewhat, Disliked it

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026